{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:59:52Z","timestamp":1782935992413,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejca.2025.115779","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:29:15Z","timestamp":1757770155000},"page":"115779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non\u2013small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102)"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-193X","authenticated-orcid":false,"given":"Yoshimasa","family":"Shiraishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shimose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-220X","authenticated-orcid":false,"given":"Motoko","family":"Tachihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tsuchiya-Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0753-4318","authenticated-orcid":false,"given":"Ryotaro","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8071-8797","authenticated-orcid":false,"given":"Hiroyuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Toi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-1193","authenticated-orcid":false,"given":"Kosuke","family":"Kashiwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3456-6833","authenticated-orcid":false,"given":"Kazunori","family":"Tobino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenobu","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-9138","authenticated-orcid":false,"given":"Yoshihiko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Chibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-4401","authenticated-orcid":false,"given":"Tomoya","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miiru","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5185-6907","authenticated-orcid":false,"given":"Shinsuke","family":"Ogusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Furuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7868-6661","authenticated-orcid":false,"given":"Satoru","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5145-9036","authenticated-orcid":false,"given":"Taishi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115779_bib1","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1074\/jbc.270.12.6531","article-title":"Lung cell-specific expression of the murine surfactant protein a (SP-A) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1","volume":"270","author":"Bruno","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2025.115779_bib2","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1074\/jbc.271.12.6881","article-title":"Transcription of the lung-specific surfactant protein c gene is mediated by thyroid transcription factor 1","volume":"271","author":"Kelly","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2025.115779_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0167-4781(96)00180-7","article-title":"Regulation of clara cell secretory protein gene transcription by thyroid transcription factor-1","volume":"1350","author":"Zhang","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejca.2025.115779_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature09881","article-title":"Suppression of lung adenocarcinoma progression by Nkx2-1","volume":"473","author":"Winslow","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.115779_bib5","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1038\/sj.onc.1211012","article-title":"Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer","volume":"27","author":"Kwei","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2025.115779_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International association for the study of lung cancer\/American thoracic society\/european respiratory society international multidisciplinary classification of lung adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2025.115779_bib7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2025.115779_bib8","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/j.cllc.2020.05.014","article-title":"Pemetrexed-Based chemotherapy is inferior to Pemetrexed-Free regimens in thyroid transcription factor 1 (TTF-1)-Negative, EGFR\/ALK-Negative lung adenocarcinoma: a propensity score matched pairs analysis","volume":"21","author":"Frost","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2025.115779_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.lungcan.2017.03.015","article-title":"Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas","volume":"108","author":"Schilsky","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2025.115779_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11845-018-1839-5","article-title":"Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy","volume":"188","author":"Doherty","year":"2019","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.ejca.2025.115779_bib11","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1097\/JTO.0b013e3182208ea8","article-title":"Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy","volume":"6","author":"Sun","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2025.115779_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317691186","article-title":"Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy","volume":"39","author":"Fiala","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ejca.2025.115779_bib13","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1200\/jco.2013.31.15_suppl.8086","volume":"31","author":"Garon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115779_bib14","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.21037\/tlcr-22-393","article-title":"Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1\/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer","volume":"11","author":"Ibusuki","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2025.115779_bib15","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115779_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115779_bib18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115779_bib19","article-title":"TTF-1 expression and clinical outcomes of combined chemoimmunotherapy in patients with advanced lung adenocarcinoma: a prospective observational study","volume":"4","author":"Katayama","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ejca.2025.115779_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1957603","article-title":"Prognostic value of thyroid transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1\/PD-L1","volume":"10","author":"Galland","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2025.115779_bib21","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/1759-7714.14560","article-title":"Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma","volume":"13","author":"Nakahama","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ejca.2025.115779_bib22","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic Non-Small-Cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115779_bib23","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115779_bib24","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.cllc.2023.04.009","article-title":"Rationale and design of the phase II ANTELOPE study of atezolizumab, carboplatin and nab-Paclitaxel vs. Pembrolizumab, platinum and pemetrexed in TTF-1 negative, metastatic lung adenocarcinoma (AIO-TRK-0122)","volume":"24","author":"Frost","year":"2023","journal-title":"Clin Lung Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T06:40:12Z","timestamp":1759214412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925005659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"alternative-id":["S0959804925005659"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115779","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non\u2013small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115779"}}